Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2015

01-03-2015 | Urologic Oncology

Coupling of Prostate and Thyroid Cancer Diagnoses in the United States

Authors: Jeffrey J. Tomaszewski, MD, Robert G. Uzzo, MD, Brian Egleston, PhD, Anthony T. Corcoran, MD, Reza Mehrazin, MD, Daniel M. Geynisman, MD, John A. Ridge, MD, PhD, Colleen Veloski, MD, Neil Kocher, MD, Marc C. Smaldone, MD, MHSc, Alexander Kutikov, MD

Published in: Annals of Surgical Oncology | Issue 3/2015

Login to get access

Abstract

Background

Prostate and thyroid cancers represent two of the most overdiagnosed tumors in the US. Hypothesizing that patients diagnosed with one of these malignancies were more likely to be diagnosed with the other, we examined the coupling of diagnoses of prostate and thyroid cancer in a large US administrative dataset.

Methods

The surveillance, epidemiology, and end results (SEER) database was used to identify men diagnosed with clinically localized prostate cancer (CaP) or thyroid cancer between 1995 and 2010. SEER*stat software was used to estimate multivariable-adjusted standardized incidence ratios (SIRs) and investigate the rates of subsequent malignancy diagnosis. Additional non-urologic cancer sites were added as control groups.

Results

Patients with thyroid cancer were much more likely to be diagnosed with CaP than patients in the SEER control group (SIR 1.28 [95 % CI 1.1–1.5]; p < 0.05). Similarly, the observed incidence of thyroid cancer was significantly higher in patients with CaP when compared with SEER controls (SIR 1.30 [95 % CI 1.2–1.4]; p < 0.05). When stratified by follow-up interval, the observed thyroid cancer diagnosis rate among men with CaP was significantly higher than expected at 2–11 (SIR 1.83 [95 % CI 1.4–2.4]), 12–59 (SIR 1.24 [95 % CI 1.0–1.5]), and 60–119 (SIR 1.25 [95 % CI 1.0–1.5]) months of follow-up. There was no increased risk of CaP or thyroid cancer diagnosis among patients with non-urologic malignancies.

Conclusions

There is a significant association of diagnoses with prostate and thyroid cancer in the US. In the absence of a known biological link between these tumors, these data suggest that diagnosis patterns for prostate and thyroid malignancies are linked.
Literature
1.
2.
Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.PubMedCentralPubMedCrossRef
3.
Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981–90.PubMedCrossRef
4.
Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–55.PubMedCrossRef
5.
Sivarajan G, Prabhu V, Taksler GB, Laze J, Lepor H. Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. Eur Urol. 2014;65(1):58–65.PubMedCrossRef
6.
Prabhu V, Sivarajan G, Taksler GB, Laze J, Lepor H. Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol. 2014;65(1):52–7.PubMedCentralPubMedCrossRef
7.
Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15(2):223–31.PubMedCrossRef
8.
9.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22.PubMedCrossRef
10.
Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nature Rev Clin Oncol. 2013;10(5):289–301.CrossRef
11.
Cancer survivors: living longer, and now, better. Lancet. 2004;364(9452):2153–4.
12.
Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol. 2010;20(1):67–78.PubMedCrossRef
13.
Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008;14(6):429–434.PubMedCrossRef
14.
Suh B, Shin DW, Kim SY, et al. Mode of primary cancer detection as an indicator of screening practice for second primary cancer in cancer survivors: a nationwide survey in Korea. BMC Cancer. 2012;12:557.PubMedCentralPubMedCrossRef
15.
16.
Pierce CA, Haut ER, Kardooni S, et al. Surveillance bias and deep vein thrombosis in the national trauma data bank: the more we look, the more we find. J Trauma. 2008;64(4):932–6; discussion 936–937.PubMedCrossRef
17.
Craig SL, Feinstein AR. Antecedent therapy versus detection bias as causes of neoplastic multimorbidity. Am J Clin Oncol. 1999;22(1):51–56.PubMedCrossRef
18.
Corcoran AT, Smaldone MC, Egleston BL, et al. Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int. 2013;112(2):161–8.PubMedCentralPubMedCrossRef
19.
Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013;347:f4706.PubMedCrossRef
20.
Knops AM, Legemate DA, Goossens A, Bossuyt PM, Ubbink DT. Decision aids for patients facing a surgical treatment decision: a systematic review and meta-analysis. Ann Surg. 2013;257(5):860–6.PubMedCrossRef
21.
22.
23.
Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF. Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol. 2012;19(6):1887–96.PubMedCrossRef
24.
Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol. 2011;98(1):81–6.PubMedCrossRef
25.
Kellen E, Zeegers MP, Dirx M, et al. Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. Eur J Cancer. 2007;43(11):1694–1700.PubMedCrossRef
26.
Johnstone PA, Powell CR, Riffenburgh R, Rohde DC, Kane CJ. Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year followup. J Urol. 1998;159(3):946–9.PubMedCrossRef
27.
Hinnen KA, Schaapveld M, van Vulpen M, et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol. 2011;29(34):4510–5.PubMedCrossRef
28.
Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91(5):1819–25.PubMedCrossRef
29.
Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol. 2005;23(34):8884–93.PubMedCrossRef
30.
Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–51.PubMedCrossRef
31.
Trask PC, Rabin C, Rogers ML, et al. Cancer screening practices among cancer survivors. Am J Prev Med. 2005;28(4):351–6.PubMedCrossRef
32.
McCabe MS, Partridge AH, Grunfeld E, Hudson MM. Risk-based health care, the cancer survivor, the oncologist, and the primary care physician. Semin Oncol. 2013;40(6):804–12.PubMedCrossRef
33.
Eisinger F, Pivot X, Coscas Y, et al. Impact of general practitioners’ sex and age on systematic recommendation for cancer screening. Eur J Cancer Prev. 2011;20 Suppl 1:S39–41.PubMedCrossRef
34.
Liu L, de Vries E, Louwman M, et al. Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer. 2011;128(7):1659–67.PubMedCrossRef
35.
Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis. Cancer. 2012;118(24):6207–16.PubMedCrossRef
36.
Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150(2):133–9.PubMedCrossRef
37.
Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur Urol. 2012;61(4):652–61.PubMedCrossRef
38.
Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg. 2011;254(6):947–50.PubMedCrossRef
39.
Suit H, Goldberg S, Niemierko A, et al. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res. 2007;167(1):12–42.PubMedCrossRef
Metadata
Title
Coupling of Prostate and Thyroid Cancer Diagnoses in the United States
Authors
Jeffrey J. Tomaszewski, MD
Robert G. Uzzo, MD
Brian Egleston, PhD
Anthony T. Corcoran, MD
Reza Mehrazin, MD
Daniel M. Geynisman, MD
John A. Ridge, MD, PhD
Colleen Veloski, MD
Neil Kocher, MD
Marc C. Smaldone, MD, MHSc
Alexander Kutikov, MD
Publication date
01-03-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4066-y

Other articles of this Issue 3/2015

Annals of Surgical Oncology 3/2015 Go to the issue

Medical Oncology

Clinicopathological Significance of CXCR4 Expression in Renal Cell Carcinoma: A Meta-Analysis

Gastrointestinal Oncology

Techniques of Reduced PRT Laparoscopy-Assisted Distal Gastrectomy (Duet LADG)

Gastrointestinal Oncology

Total Gastrectomy for Gastric Cancer: An Analysis of Postoperative and Long-Term Outcomes Through Time

Thoracic Oncology

The Impact of Tumor Cell Differentiation on Survival of Patients with Resectable Esophageal Squamous Cell Carcinomas

Pancreatic Tumors

Surgical Management of Advanced Pancreatic Neuroendocrine Tumors: Short-Term and Long-Term Results from an International Multi-institutional Study

Colorectal Cancer

Impact of Perineural and Lymphovascular Invasion on Oncological Outcomes in Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy and Surgery